2015 biopharmaceutical dealmaking expected to set a new record for M&A and licensing; report

A survey of biopharmaceutical dealmakers by Campbell Alliance, the consulting firm of inVentiv Health, suggests that 2015 will set a new record for mergers and acquisitions and licensing of biopharmaceutical assets. The survey also revealed early signs of a potential slow-down in licensing of assets.

This is the seventh year that Campbell Alliance has surveyed dealmakers to provide a forward-looking glimpse of what the rest of the year will hold and identify areas of greatest opportunities for buyers and sellers. A report on the survey was released during a Super Session yesterday at the BIO International Convention in Philadelphia, "Riding the Bull Market: What's in Store for Biotech Dealmakers in 2015?"

"The level of dealmaking activity last year was the highest it has been since 2009 and activity in 2015 is set to surpass it," said Neel Patel, vice president, Campbell Alliance. "But this time, M&A activity is being fueled by small and mid-cap biopharma buyers, who are flush with cash. And the details of what we found across the sector should be of interest to anyone evaluating buying or selling an asset in 2015," he noted.